Genotype-Phenotype Correlation in Cardiovascular Disease

Overview

Información sobre este estudio

This research study is being done to help characterize cardiovascular disease and improve diagnostic tests.

OBJECTIVES

  1. To understand the pathogenesis, molecular mechanisms, and disease progression of heritable cardiovascular disease

  2. To evaluate the incidence of occult heritable cardiovascular disease in various populations.

  3. To correlate imaging and pathological phenotype with genotype to the ends described above.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Patients/decedents must have cardiovascular disease that is clinically, radiologically or pathologically identified.

  • Prospectively identified patient is willing to undergo session(s) with a genetic counselor (GC) to discuss results, should they be relevant to their medical care.

  • Prospectively identified patients must understand and provide written informed consent and HIPAA authorization prior to enrollment in the study.

    • If the patient or family member who is being enrolled is not English speaking, the approved institutional procedures for interfacing with non-English speaking prospective subjects who are not specifically targeted for the project. This includes:

      • Having an independent medical interpreter provide an oral explanation (in person or by phone) of the entire content of the English version of the approved consent document to the prospective subject or the legally-recognized next-of-kin.

      • Using the IRB's written Short Form / Authorization to Use and Disclose Protected Health Information form, stating that the elements of informed consent have been presented orally. A short form that has be translated into a language understandable to the subject will be provided.

      • Having a witness, who might be the interpreter, to the oral presentation who is conversant in both the English language and the language of the prospective subject.

      • Making certain that the prospective subject or his/her representative has signed the translated Short Form/Authorization to Use and Disclose Protected Health Information form.

      • Making certain that the witness has signed both the translated Short Form and a copy of the English consent document.

      • Making certain that the person obtaining consent has signed a copy of the English consent document.

      • Making certain a copy of the translated Short Form and a copy of the English consent document are given to the prospective subject or the prospective subject's representative.

Exclusion Criteria:

  • Patients with psychiatric illness or social situations that would limit compliance with the study requirements or the ability to provide, willingly, written informed consent.

  • Women who are pregnant at the time of surgery.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Joseph Maleszewski, M.D.

Abierto para la inscripción

Contact information:

Jenna Capelle

(507) 266-5017

Capelle.Jenna@mayo.edu

More information

Publicaciones

Publications are currently not available